中國心連心化肥(01866.HK)擬1.42億元控股新三板公司
格隆匯2月24日丨中國心連心化肥(01866.HK)宣佈,於2020年2月24日,公司全資附屬公司氫力能源達成協議,擬以總代價人民幣1.42億元認購及收購瑞誠科技共3187.5萬股股份,佔其擴大後總股本的51%。
瑞誠科技主營業務為醫藥中間體、核苷類產品的研發、生產和銷售。2016年4月12日,新鄉瑞誠科技的股票在新三板掛牌交易(股份代號:836437)。於公告日期,目標公司的註冊資本為人民幣5250萬元
交易全部完成後,瑞誠科技將成為公司的附屬公司,可拓展集團業務及加強盈利水平。另外,集團也可利用新三板作為額外的融資平台,拓展融資渠道。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.